News | April 20, 2012

Innovative TAVR Access/Closure Device Featured at EuroPCR

April 20, 2012 — VasoStitch will be featuring its technology at EuroPCR, Europe’s largest interventional cardiology scientific meeting, May 17, in Paris. The company is developing a percutaneous access-and-closure system for the nonsurgical deployment of large-diameter transcatheter therapeutic devices, such as transcatheter aortic valve implants (TAVI) and endovascular aneurysm repair (EVAR) devices. This system is designed to reduce procedural complexity and eliminate the need for open surgery.

The challenge with percutaneous catheter-based cardiac procedures is that a surgical cut-down is required for access and then closure. VasoStitch has developed two platform technologies designed to access and close percutaneous therapy sites without the need for open surgery, thus making catheter-based interventions simpler and more accessible.

“At the present time, surgical means of arterial or cardiac access-and-closure for large-diameter, catheter-based interventions such as TAVI adds about 60 minutes to an already lengthy and elaborate procedure. As a result, a device that can duplicate the current ‘gold standard’ of surgical access and repair — but in a quicker and simpler, nonsurgical procedure — will surely stimulate the adoption of large-diameter cardiovascular and endovascular therapies, as well as improve the efficiency of patient management,” said David W. J. Smith, president and CEO of VasoStitch. “We are moving quickly toward our first-in-human milestone.”

The VasoStitch presentation at EuroPCR will be made by the company’s founder, Amir Belson, M.D.

For more information: www.vasostitch.com

Related Content

FDA Approves Vascade MVP Vascular Closure System
Technology | Vascular Closure Devices | December 20, 2018
Cardiva Medical Inc. announced the company has received premarket approval (PMA) from the U.S. Food and Drug...
PerQseal Large Bore Closure Device Launches in Europe
News | Vascular Closure Devices | November 21, 2018
Vivasure Medical Ltd. recently announced the European launch of the PerQseal closure device for large-bore...
Vascade MVP Reduces Time to Ambulation Follow EP Procedures
News | Vascular Closure Devices | November 11, 2018
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Overlay Init